Publications by authors named "T Puthanakit"
Pharmacokinetics of Generic Pediatric Abacavir/Lamivudine Dispersible Tablets in Thai Young Children Living With HIV Weighing Below Twenty Kilograms.
Pediatr Infect Dis J
January 2025
Article Synopsis
- A study was conducted on the pharmacokinetics of generic abacavir/lamivudine dispersible tablets in Thai children with HIV, aged between 3 months and under 7 years old, weighing 6 to under 20 kg.
- Twenty-eight children received a combination of abacavir/lamivudine plus dolutegravir once daily, with dosages based on their weight categories as per WHO guidelines.
- The drug exposure levels (AUC0-24 h) for both abacavir and lamivudine were found to be within the target ranges, supporting the current WHO weight band dosing recommendations for this population.
The global strategy to #EndAIDS is underpinned by a call to end all inequities and to ensure no-one is left behind; but inequities continue, and people are still being left behind. Despite the advances seen in some populations and in some geographical areas, with ongoing high rates of HIV vertical transmission, ending HIV for pregnant and breastfeeding women and their children must be prioritised urgently. Focused on Asia and the Pacific, the region with the second largest number of people with HIV, in this viewpoint we highlight the heterogenous nature of global and regional success in eliminating vertical transmission of HIV.
View Article and Find Full Text PDFTherapeutic Drug Monitoring of High-dose Sulbactam in Pediatric Patients: Preliminary Data From a Prospective Observational Pharmacokinetic Study.
Pediatr Infect Dis J
October 2024
Background: Rates of carbapenem-resistant Acinetobacter baumannii are rising in Thailand. Although high-dose (HD) sulbactam is recommended for treating carbapenem-resistant A. baumannii infections, data on plasma sulbactam concentrations in children are limited.
View Article and Find Full Text PDFArticle Synopsis
- The study investigated the prevalence of hepatitis C virus (HCV) infection among Thai adolescents and young adults (AYA) aged 15-24 who visit HIV/sexual health clinics in Bangkok.
- Approximately 2.7% of the 300 participants were found to be HCV positive, with a notably higher prevalence of 5.6% among those living with HIV.
- The research highlighted that drug use significantly increased the risk of HCV infection, suggesting the need for targeted screenings in healthcare settings to improve early detection and treatment.
A reduced-dose recombinant pertussis vaccine booster in Thai adolescents: a phase 2/3, observer-blinded, randomised controlled, non-inferiority trial.
Lancet Child Adolesc Health
December 2024
Article Synopsis
- The study aimed to evaluate a new low-cost pertussis booster vaccine with reduced doses of key components, comparing it to existing Tdap vaccines, due to a recent increase in pertussis cases.
- Conducted in Thailand with 450 adolescents, the trial tested seroconversion rates among three vaccine groups to determine if the new vaccine was non-inferior compared to traditional options.
- Results showed that the new vaccine (ap) had a 71% seroconversion rate for anti-FHA IgG, while Tdap had a higher rate of 94%, suggesting that the new vaccine still needs further investigation to improve immunogenicity.